Achieve Life Sciences, Inc. QUIT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.32M | 14.58M | 7.17M | 10.86M | 9.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.54M | 18.39M | 10.46M | 14.73M | 14.69M |
| Operating Income | -20.54M | -18.39M | -10.46M | -14.73M | -14.69M |
| Income Before Tax | -12.11M | -74.77M | -10.17M | -14.66M | -14.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.11M | -74.77M | -10.17M | -14.66M | -14.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.11M | -74.77M | -10.17M | -14.66M | -14.44M |
| EBIT | -20.54M | -18.39M | -10.46M | -14.73M | -14.69M |
| EBITDA | -20.48M | -18.34M | -10.41M | -14.67M | -14.64M |
| EPS Basic | -0.11 | -0.80 | -0.19 | -0.28 | -0.28 |
| Normalized Basic EPS | -0.07 | -0.50 | -0.12 | -0.17 | -0.18 |
| EPS Diluted | -0.11 | -0.80 | -0.19 | -0.28 | -0.28 |
| Normalized Diluted EPS | -0.07 | -0.50 | -0.12 | -0.17 | -0.18 |
| Average Basic Shares Outstanding | 105.48M | 93.51M | 53.38M | 53.28M | 51.02M |
| Average Diluted Shares Outstanding | 105.48M | 93.51M | 53.38M | 53.28M | 51.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |